Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
is a Gram-negative pathogen responsible for nosocomial infections. The exploration of novel therapeutic targets within its proteome is essential for developing successful therapies for combating infections caused by this organism. Employing in silico approaches, this study aims to identify drug targets from hypothetical proteins of . These proteins were extracted from complete proteomes of 351 strains of after removing duplicates and taxonomically misclassified strains. The essentiality analysis revealed the presence of 1923 essential hypothetical proteins (EHPs) in these strains. These proteins were characterized based on physicochemical properties, subcellular locations, antimicrobial resistance, virulence and druggability. The domain analysis and functional annotation classified these as enzymes, transporters, and secretion proteins. Among these annotated proteins, 149 EHPs were found to be virulent proteins. The majority of these proteins are found to be involved in antibiotic inactivation and antibiotic efflux pumps. One hypothetical protein was characterized as a small multidrug resistance (SMR) efflux pump protein. Sixty-one EHPs were identified as potential drug targets, and 33 among these were identified in 15 different strains. The network analysis on these targets revealed a hub protein cobH, along with small clusters and singletons. These drug targets can be identified and validated experimentally before exploiting them in development of drugs against .
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12392004 | PMC |
| http://dx.doi.org/10.1021/acsomega.5c02268 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic Association of Lipids and Lipid-Lowering Drug Target Genes With Atopic Dermatitis: A Drug Target Mendelian Randomization Study.
Health Sci Rep
September 2025
Department of Dermatology the Union Hospital, Fujian Medical University Fuzhou People's Republic of China.
Background And Aims: Several observational studies have reported inconsistent associations between dyslipidaemia, stains use and atopic dermatitis (AD). Nevertheless, the available data on the effects of -C-lowering as well as TG-lowering drugs remain inconclusive and limited. The aim of this study was to evaluate the causal association of lipid traits and long-term use of lipid-lowering drugs on AD risk.
View Article and Find Full Text PDFWhen is A Kidney Biopsy Indicated During the Treatment of Brain Cancer?
Eur J Case Rep Intern Med
August 2025
Nephrology Department, Unidade Local de Saúde de Braga, Braga, Portugal.
Introduction: Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) and is widely used in oncology for its anti-angiogenic properties. However, VEGF inhibition may result in significant nephrotoxicity, including thrombotic microangiopathy (TMA). While systemic TMA is well-described, isolated renal-limited TMA remains under recognised.
View Article and Find Full Text PDFLineage Switch of Adult B-Cell Acute Lymphoblastic Leukaemia to Acute Myeloid Leukaemia Following B-Cell-Directed Therapy.
Eur J Case Rep Intern Med
August 2025
Division of Hematology and Oncology, UNM Comprehensive Cancer Center, Albuquerque, USA.
Background: Blinatumomab and inotuzumab ozogamicin (InO) are B-cell targeted agents used in the frontline and relapsed/refractory treatment of B-cell acute lymphoblastic leukaemia (B-ALL). Blinatumomab, a bispecific T-cell engager that targets CD19 and CD3, and InO, an antibody-drug conjugate targeting CD22, have both shown efficacy. However, recent reports have noted lineage conversion as a complication when these agents are used individually or sequentially.
View Article and Find Full Text PDFIntegrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immunomodulation and targeted therapy.
Front Immunol
September 2025
Department of Thoracic Surgery, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, Guangdong, China.
Background: Lung cancer remains the leading cause of cancer-related mortality globally, primarily due to late-stage diagnosis, molecular heterogeneity, and therapy resistance. Key biomarkers such as EGFR, ALK, KRAS, and PD-1 have revolutionized precision oncology; however, comprehensive structural and clinical validation of these targets is crucial to enhance therapeutic efficacy.
Methods: Protein sequences for EGFR, ALK, KRAS, and PD-1 were retrieved from UniProt and modeled using SWISS-MODEL to generate high-confidence 3D structures.
Advances in neuroscientific mechanisms and therapies for glioblastoma.
iScience
September 2025
Department of Molecular Pathology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, QingDao, Shandong 266300, China.
Gliomas are common primary brain tumors in the central nervous system, characterized by invasiveness, heterogeneity, and drug resistance, posing a threat to patients' lives. Glioblastoma (IDH wild-type) exhibits the highest invasiveness and mortality rate, making it a challenging therapeutic target. This review first outlines the characteristics of gliomas and their impact on the nervous system, then explores the pathological mechanisms and unique behaviors of glioblastoma (IDH wild-type), as well as the influence of the nervous system on its occurrence and progression.
View Article and Find Full Text PDF